Abstract: The present invention is in the field of a National Individual Floating Transportation Infrastructure (NIfTI) wherein floating vehicles can travel by magnetic levitation and propagation. The vehicles can travel at a controllable height above the existing, albeit modified, road infrastructure and at relatively high speeds.

Abstract: The present invention relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Stargardt disease.

Abstract: The present invention is in the field of a device comprising an adaptable and addressable neuromorphic structure, a method of operating said neuromorphic structure, a method of acquiring a distribution of states of said neuromorphic structure, and a method of adapting a micro-electronic or nano-electronic device comprising said neuromorphic structure.

Abstract: The invention provides a method for performing a magnetic resonance measurement of an element in a target region, wherein the element has a magnetic resonance excitation spectrum peak with a linewidth LR, wherein the method comprises a measurement cycle (100) comprising: a magnetization transfer stage (110) comprising providing a plurality of pulses (115) of first radiation to the target region, wherein the plurality of pulses (115) are selected to provide a net pulse having a net pulse angle ?N?1°, and wherein the first radiation comprises a first frequency spectrum peak having a first linewidth LF, wherein the first frequency spectrum peak at least partially overlaps with the magnetic resonance excitation spectrum peak, and wherein LF>5*LR; an excitation stage (130) comprising providing a radio frequency pulse to the target region, wherein the radio frequency pulse excites the element resulting in a transverse magnetization of the element; and a measurement stage (140) comprising detecting a signal from

Abstract: The present invention relates to the field of medicine.

Abstract: A heart support device for circulatory assistance is disclosed. The device comprises a chamber body (10) defining a chamber having an internal volume configured to be filled with blood. The chamber body (10) has a first opening (12) and the chamber is dimensioned such that the first opening (12) and the chamber are fully disposed within a chamber of the human heart. A dynamic volume body (14) is provided and configured to be inflated or deflated to alternately increase or decrease the interior volume of the chamber. A catheter (16) comprising at least one lumen in fluid communication with the dynamic volume body is configured to deliver fluid to the dynamic volume body to inflate the dynamic volume body. A directional flow structure is configured to direct a flow of blood out of the chamber in a direction substantially aligned with a direction in which the catheter (16) extends.

Abstract: The present invention relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Stargardt disease.

Abstract: The present invention is in the field of a National Individual Floating Transportation Infrastructure (NIfTI) wherein floating vehicles can travel by magnetic levitation and propagation. The vehicles can travel at a controllable height above the existing, albeit modified, road infrastructure and at relatively high speeds.

Abstract: The present invention relates to the field of medicine.

Abstract: The present invention relates to the field of medicine. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Stargardt disease.

Abstract: A heart support device for circulatory assistance is disclosed. The device comprises a chamber body (10) defining a chamber having an internal volume configured to be filled with blood. The chamber body (10) has a first opening (12) and the chamber is dimensioned such that the first opening (12) and the chamber are fully disposed within a chamber of the human heart. A dynamic volume body (14) is provided and configured to be inflated or deflated to alternately increase or decrease the interior volume of the chamber. A catheter (16) comprising at least one lumen in fluid communication with the dynamic volume body is configured to deliver fluid to the dynamic volume body to inflate the dynamic volume body. A directional flow structure is configured to direct a flow of blood out of the chamber in a direction substantially aligned with a direction in which the catheter (16) extends.

Abstract: A polymer hydrogel having a polymer formed by the crosslinking reaction of a polymeric unit A according to formula (I), with a crosslinking unit B according to formula (II) and water, wherein n=100-10,000, preferable 250-2500, more preferable 500-1500; m=independently 2-10, preferably 3 or 4; FG is a functional moiety that can be covalently coupled to the complementary functional moiety F1 or F2 of the crosslinking unit (B); k=0.01-0.05; h=0, 1 or 2; the spacer is an organic moiety, having a main chain comprising at least two functional moieties F1 and F2, wherein the length of the crosslinker in the extended conformation as determined by molecular modeling (including spacer and functional groups F1 and F2) is between 2.5 and 12 nm, or wherein the length is between 20 and 80 atoms.

Abstract: The present invention relates to the field of medicine, specifically the field of treatment and prevention of cardiovascular diseases.

Abstract: The present invention relates to a new class of sialyltransferase inhibitors. The class features a carbamate or similar moiety on the amine of a neuraminic acid derivative. Such inhibitors are suitable for use as a medicament, for example for treating, preventing, or delaying bacterial infection, viral infection, cancer, a disorder of sialic acid metabolism, or an autoimmune disease.

Abstract: The present invention relates to the field of medicine. In particular, it relates to therapy for the treatment of Usher syndrome type 2a and USH2A-associated retinitis pigmentosa.

Abstract: A system for filtering an input image dataset is disclosed. A plurality of sequences of input signal values, wherein each sequence corresponds to a different attribute, wherein an input signal value is associated with an attribute and a sampling point i. At least one processor 4 is configured to control computing an output signal value corresponding to a sampling point and an attribute. For a particular sampling point i and for each of a plurality of different attributes of the set of attributes, associating a weight to an input signal value based on a similarity between the signal value and for a plurality of the sampling points j excluding the sampling point i. Also the system computes a weighted sum based on the input signal values and weights. The attribute is a location or a frequency.

Abstract: The present invention relates to the field of medicine.

Abstract: Described herein are method, compositions and kits for prognosis of prostate cancer. The methods include determining the ratio of PCA3 and of a prostate-specific marker expression in a urine sample and correlating the value of the PCA3/prostate-specific marker ratio with the aggressiveness and mortality risk of prostate cancer in the subject. The method for prognosing prostate cancer in a sample of a patient includes assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of prostate-specific marker in the sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of prostate-specific marker; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.

Abstract: The invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Usher syndrome type 2A and/or USH2A-associated non syndromic retina degeneration.

Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis.